GSK PLC (GSK)
33.35
-1.04
(-3.02%)
USD |
NYSE |
Nov 15, 16:00
32.98
-0.37
(-1.11%)
After-Hours: 16:35
GSK Free Cash Flow (Quarterly): 1.749B for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 1.749B |
June 30, 2024 | 843.95M |
March 31, 2024 | 501.01M |
December 31, 2023 | 2.958B |
September 30, 2023 | 2.176B |
June 30, 2023 | 949.07M |
March 31, 2023 | -578.58M |
December 31, 2022 | 1.674B |
September 30, 2022 | 737.05M |
June 30, 2022 | 1.314B |
March 31, 2022 | 2.646B |
December 31, 2021 | 4.424B |
September 30, 2021 | 1.866B |
June 30, 2021 | 1.031B |
March 31, 2021 | -31.71M |
December 31, 2020 | 4.212B |
September 30, 2020 | 430.57M |
June 30, 2020 | 2.898B |
March 31, 2020 | 795.95M |
December 31, 2019 | 3.574B |
September 30, 2019 | 2.474B |
June 30, 2019 | 962.73M |
March 31, 2019 | 467.69M |
December 31, 2018 | 4.748B |
September 30, 2018 | 2.054B |
Date | Value |
---|---|
June 30, 2018 | 1.331B |
March 31, 2018 | 706.38M |
December 31, 2017 | 2.784B |
September 30, 2017 | 1.868B |
June 30, 2017 | 535.18M |
March 31, 2017 | 901.66M |
December 31, 2016 | 3.101B |
September 30, 2016 | 1.592B |
June 30, 2016 | 1.090B |
March 31, 2016 | -166.06M |
December 31, 2015 | 1.261B |
September 30, 2015 | 55.44M |
June 30, 2015 | -303.21M |
March 31, 2015 | 7.579M |
December 31, 2014 | 2.639B |
September 30, 2014 | 1.408B |
June 30, 2014 | 642.38M |
March 31, 2014 | 956.35M |
December 31, 2013 | 2.693B |
September 30, 2013 | 2.541B |
June 30, 2013 | 1.959B |
March 31, 2013 | 1.445B |
December 31, 2012 | 2.212B |
September 30, 2012 | -1.068B |
June 30, 2012 | 2.191B |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-578.58M
Minimum
Mar 2023
4.424B
Maximum
Dec 2021
1.709B
Average
1.494B
Median
Free Cash Flow (Quarterly) Benchmarks
AstraZeneca PLC | 2.417B |
Pfizer Inc | 6.063B |
Autolus Therapeutics PLC | -51.92M |
Moderna Inc | -1.717B |
Biodexa Pharmaceuticals PLC | -- |